Effect of Low-Dose Baclofen Administration on the GH-IGF1 Axis Study
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
Insulin-like growth factor I (IGF-I) is used as a measure of the body's ability to produce
growth hormone. Growth hormone is important for muscle tissue as well as many other tissues
in the body. Growth hormone (GH) and IGF-I have been shown to be reduced in many persons with
SCI. Baclofen is a FDA approved drug that is used to treat spasticity. Persons receiving
long-term baclofen therapy have been demonstrated to have increased growth hormone and IGF-I
levels. IGF-I levels will be determined before and after treatment with baclofen. In this
study, the investigators will determine the minimum dose of baclofen at which improvements in
GH and IGF-1 levels occur.
Phase:
N/A
Details
Lead Sponsor:
US Department of Veterans Affairs VA Office of Research and Development